Invitrogen

Human CD80 (aa 114-179) Control Fragment Recombinant Protein

Name: Human CD80 (aa 114-179) Control Fragment Recombinant Protein
Brand: Invitrogen
SKU: RP-103871

View all (3) CD80 (B7-1) proteins

Datasheet

Tech Support

Datasheet

Tech Support

Product Details

RP-103871

Applications

Tested Dilution

Publications

Control (Ctrl)

Assay-dependent

Blocking Assay (BLOCK)

Assay-dependent

Product Specifications

Species

Human

Expression System

E. coli

Amino acid sequence

YECVVLKYEKDAFKREHLAEVTLSVKADFPTPSISDFEIPTSNIRRIICSTSGGFPEPHLSWLENG

Tag

His-ABP-tag

Class

Recombinant

Type

Protein

Purity

>80% by SDS-PAGE and Coomassie blue staining

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

≥5.0 mg/mL

Purification

purified

Storage buffer

1M urea/PBS, pH 7.4

Contains

no preservative

Storage conditions

-20°C, Avoid Freeze/Thaw Cycles

Product Specific Information

Highest antigen sequence indentity to the following orthologs: Mouse (53%), Rat (53%).

This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-83990. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.

Target Information

CD80 (B7-1) and CD86 (B7-2) are ligands of T cell critical costimulatory molecule CD28, and of an inhibitory receptor CTLA-4 (CD152). Both B7 molecules are expressed on professional antigen-presenting cells and are essential for T cell activation, and both molecules can also substitute for each other in this process. CD80 is rapidly induced on the surface of in vitro activated B cells, with Epstein Barr Virus (EBV) transformed B cell lines, with Burkitts lymphoma cell lines, with freshly isolated follicular B lymphoma cells, T cells, and monocytes. The B-lymphocyte activation antigen B7-1 provides regulatory signals for T lymphocytes as a consequence of binding to the CD28 and CTLA4 ligands of T cells. Diseases associated with CD80 dysfunction include gallbladder squamous cell carcinoma and myocarditis.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

References (0)

Have you cited this product in a publication?

Let us know so we can reference it here.

Cite this product

Bioinformatics

Protein Aliases: Activation B7-1 antigen; B-lymphocyte activation antigen B7; B7; BB1; CD80; CD80 antigen (CD28 antigen ligand 1, B7-1 antigen); costimulatory factor CD80; costimulatory molecule variant IgV-CD80; CTLA-4 counter-receptor B7.1; sCD 80; sCD80; soluble CD 80; soluble CD80; T-lymphocyte activation antigen CD80; TS/A-1